Top

Published in:

01-12-2023 | Cytostatic Therapy | Research

Difficulty of adjuvant chemotherapy administration in patients with biliary tract cancer

Authors: Tatsuaki Sumiyoshi, Kenichiro Uemura, Ryuta Shintakuya, Kenjiro Okada, Kenta Baba, Takumi Harada, Masahiro Serikawa, Yasutaka Ishii, Shinya Nakamura, Koji Arihiro, Yoshiaki Murakami, Shinya Takahashi

Published in: Langenbeck's Archives of Surgery | Issue 1/2023

Abstract

Purpose

This study aimed to elucidate the difficulty of adjuvant chemotherapy administration in patients with biliary tract carcinoma (BTC).

Methods

Clinical data of patients with BTC who underwent curative-intent surgery were retrospectively analyzed. The eligible patients were stratified into two groups according to the presence or absence of adjuvant chemotherapy administration (adjuvant and non-adjuvant groups), and the clinicopathological features were compared between the two groups. The ratios of adjuvant chemotherapy administration were investigated in each surgical procedure. Independent factors associated with no administration of adjuvant chemotherapy were analyzed using multivariate analyses.

Results

Among 168 eligible patients, 141 (83.9%) received adjuvant chemotherapy (adjuvant group), while 27 (16.1%) did not (non-adjuvant group). The most common surgical procedure was pancreaticoduodenectomy in the adjuvant group, and it was hepatectomy with extrahepatic bile duct resection (BDR) in the non-adjuvant group, respectively. The rate of no adjuvant chemotherapy was significantly higher in patients who underwent hepatectomy with BDR than in those who underwent other surgeries (p < 0.001). The most common cause of no adjuvant chemotherapy was bile leak in 12 patients, which occurred after hepatectomy with BDR in ten patients. Multivariate analyses revealed that hepatectomy with BDR and preoperative anemia were independently associated with no adjuvant chemotherapy (p < 0.001 and p < 0.001, respectively).

Conclusions

Hepatectomy with BDR and subsequent refractory bile leak can be the obstacle to adjuvant chemotherapy administration in patients with BTC.

Available only for authorised users

Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ et al (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507–517PubMedPubMedCentralCrossRef

de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341:1368–1378PubMedCrossRef

Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma — evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15:95–111PubMedCrossRef

Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC (2002) Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37:806–813PubMedCrossRef

Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A et al (2001) Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut 48:816–820PubMedPubMedCentralCrossRef

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N et al (2013) Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. J Gastrointest Surg 17:1429–1439PubMedCrossRef

Nagahashi M, Shirai Y, Wakai T, Sakata J, Ajioka Y, Nomura T et al (2010) Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinoma. Cancer 116:400–405PubMedCrossRef

Blom D, Schwartz SI (2001) Surgical treatment and outcomes in carcinoma of the extrahepatic bile ducts: the University of Rochester experience. Arch Surg 136:209–215PubMedCrossRef

Kamposioras K, Anthoney A, Fernández Moro C, Cairns A, Smith AM, Liaskos C (2014) Impact of intrapancreatic or extrapancreatic bile duct involvement on survival following pancreatoduodenectomy for common bile duct cancer. Br J Surg 101:89–99PubMedCrossRef

10.

Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG et al (2005) Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg 241:77–84PubMedPubMedCentralCrossRef

11.

Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J et al (2005) Prognostic factors of surgical resection in middle and distal bile duct cancer: ana nalysis of 55 patients concerning the significance of ductal and radial margins. Surgery 137:396–402PubMedCrossRef

12.

Kobayashi A, Miwa S, Nakata T (2010) Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg. 97:56–64PubMedCrossRef

13.

Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A et al (2017) Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg 104:426–433PubMedCrossRef

14.

Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP et al (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61:1657–1669PubMedCrossRef

15.

Ebata T, Kosuge T, Hirano S, Unno M, Yamamoto M, Miyazaki M et al (2014) Proposal to modify the International Union against Cancer staging system for perihilar cholangiocarcinomas. Br J Surg 101:79–88PubMedCrossRef

16.

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H (2009) Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 250:950–956PubMedCrossRef

17.

Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomized, controlled, multicentre, phase 3 study. Lancet Oncol 20:663–673PubMedCrossRef

18.

Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E et al (2019) A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208). Ann Surg 270:230–237PubMedCrossRef

19.

Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T et al (2023) Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 401:195–203PubMedCrossRef

20.

Sakamoto Y, Sano T, Shimada K, Kosuge T, Kimata Y, Sakuraba M et al (2006) Clinical significance of reconstruction of the right hepatic artery for biliary malignancy. Langenbeck’s Arch Surg 391:203–208CrossRef

21.

Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M et al (2010) Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg 252:115–123PubMedCrossRef

22.

Nagino M, Kamiya J, Arai T, Nishio H, Ebata T, Nimura Y (2006) “Anatomic” right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma. Ann Surg 243:28–32PubMedPubMedCentralCrossRef

23.

Takagi T, Yokoyama Y, Kokuryo T, Ebata T, Ando M, Nagino M (2017) A clear difference between the outcomes after a major hepatectomy with and without an extrahepatic bile duct resection. World J Surg 41:508–515PubMedCrossRef

24.

Terasaki F, Hirakawa S, Tachimori H, Sugiura T, Nanashima A, Komatsu S et al (2023) Morbidity after left trisectionectomy for hepato-biliary malignancies: an analysis of the National Clinical Database of Japan. J Hepatobiliary Pancreat Sci. https://doi.org/10.1002/jhbp.1358

25.

Matsuda T, Umeda Y, Matsuda T, Endo Y, Sato D, Kojima T et al (2021) Preoperative prognostic nutritional index predicts postoperative infectious complications and oncological outcomes after hepatectomy in intrahepatic cholangiocarcinoma. BMC Can 21:708PubMedPubMedCentralCrossRef

26.

Terasaki F, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R et al (2021) Use of preoperative controlling nutritional status (CONUT) score as a better prognostic marker for distal cholangiocarcinoma after pancreatoduodenectomy. Surg Today 51:358–365PubMedCrossRef

Title: Difficulty of adjuvant chemotherapy administration in patients with biliary tract cancer
Authors: Tatsuaki Sumiyoshi
Kenichiro Uemura
Ryuta Shintakuya
Kenjiro Okada
Kenta Baba
Takumi Harada
Masahiro Serikawa
Yasutaka Ishii
Shinya Nakamura
Koji Arihiro
Yoshiaki Murakami
Shinya Takahashi
Publication date: 01-12-2023
Publisher: Springer Berlin Heidelberg
Keyword: Cytostatic Therapy
Published in: Langenbeck's Archives of Surgery / Issue 1/2023
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-023-03169-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Difficulty of adjuvant chemotherapy administration in patients with biliary tract cancer

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Open vs robotic gastrectomy with D2 lymphadenectomy: a propensity score-matched analysis on 1469 patients from the IMIGASTRIC prospective database

Surgeon’s narcissism, hostility, stress, bullying, meaning in life and work environment: a two-centered analysis

Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy

Regional transplant rates depend more on physician-dependent variables than on proximity to transplant center

Long-term outcome and cancer incidence after lower extremity bypass surgery in patients with critical limb threatening ischemia

Short-term outcomes of sleeve gastrectomy plus uncut jejunojejunal bypass (SG–uncut JJB) in patients with obesity: a preliminary prospective cohort study